Innovate and prosper, stagnate and perish. The 13th Edition of Trends Shaping U.S. Pharmaceutical Industry Strategiesreport is designed to challenge senior management thinking and strategic assumptions - to force the hard questions that make the difference between status quo strategies that doom companies and proactive strategies that leverage resources to create increasing shareholder returns. The "Trends" report is designed to challenge conventional thinking, fight "Group Think", inject fresh/different ways of looking at pharmaceuticals.and to question product development, marketing, business development, and company strategies. It is an effective tool for the orientation of senior management employees new to the pharmaceuticals industry and serves as an excellent reference source for presentations and issues discussions.& ; & ; & ; The 13th Edition of the Trends Shaping U.

S. Pharmaceuticals Industry Strategies report provides insights how the transformation of the respective United States healthcare industry market segments/stakeholders will redefine how drugs are identified, developed, reimbursed, launched, marketed, prescribed, dispensed, and taken by patients. The period to 2020 presents opportunities for companies to redefine industry norms in select therapeutic and/or product categories to create a competitive advantage.& ; & ; U.S. Pharmaceuticals represents an industry undergoing redefinition and revitalization. The 2012 to 2020 period will be typified by industry discontinuities, innovation and change. What worked in the past will not work in the future.

Pharmaceutical industry norms in 2020 will be radically different than they were at the end of 2011.& ; & ; Objective, fact-based strategic planning will be the difference between success and failure for most pharmaceutical, biotechnology and generics drug companies. Strategically managed companies will anticipate and capitalize on industry change, innovate and prosper; the remainder will be broken up, acquired, merged or driven out of business. The 13th Edition of the Trends Shaping U.S. Pharmaceuticals Industry Strategies report is designed to challenge internal assumptions and corporate strategies to assist management in refining strategies to better position the company to capitalize on industry change.